3/3/2015 8:17 AM IPN.PA 45.96 € (+1.23 %) Data: Yahoo Finance
Startsidan

Press Releases

  • 3/3/2015

    Ipsen’s 2014 results and 2015 financial objectives

    Ipsen’s 2014 results and 2015 financial objectives
  • 3/2/2015

    Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015

    Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015
  • 3/2/2015

    Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer

    Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer
  • 2/24/2015

    Ipsen enters into option agreement to acquire Canbex Therapeutics

    Ipsen enters into option agreement to acquire Canbex Therapeutics
  • 2/3/2015

    Ipsen: sales in the fourth quarter and full year 2014

    Ipsen: sales in the fourth quarter and full year 2014
  • 1/26/2015

    Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

    Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults
  • 1/7/2015

    Ipsen announces its corporate agenda for 2015

    Ipsen announces its corporate agenda for 2015
  • 12/16/2014

    Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

    Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
  • 12/16/2014

    François Garnier appointed Executive Vice President, General Counsel of Ipsen

    François Garnier appointed Executive Vice President, General Counsel of Ipsen
  • 12/12/2014

    Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen

    Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen